Key Highlights
- Silence Therapeutics' Phase 2 SANRECO trial of divesiran met its primary endpoint.
- 88% of patients reached clinical response, compared to 19% for placebo.
- The therapy significantly lowered phlebotomy requirements across dosing groups.
- Management is planning a Phase 3 launch in the first half of 2027.
Silence Therapeutics ( Nasdaq : SLN) announced that its Phase 2 SANRECO trial of divesiran in phlebotomy-dependent polycythemia vera achieved its primary endpoint, with 88% of patients reaching clinical response compared to 19% for placebo.
What Happened
The therapy significantly lowered phlebotomy requirements across both Q6W and Q12W dosing groups, with management planning a Phase 3 launch in the first half of 2027.
Phlebotomy, the repeated removal of blood, is the current standard approach for managing polycythemia vera but carries a significant treatment burden for patients, making a therapy that meaningfully reduces this requirement a potentially significant advance for the condition.
Market Reaction
The disclosed information does not include stock price or trading data for Silence Therapeutics following the trial results.
The magnitude of the response rate difference between divesiran and placebo, 88% versus 19%, represents an unusually large treatment effect for a Phase 2 trial, which may support a strong evidentiary basis heading into the planned Phase 3 program.
Outlook
The planned Phase 3 launch in the first half of 2027 represents the next major disclosed milestone for divesiran in polycythemia vera.
Given the strength of the Phase 2 response rate, investors are likely to watch for details on the Phase 3 trial design and enrollment timeline as the program transitions toward its next stage of development.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...